Please assess the completion status of the following clinical trial:

Trial Title: Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and Female, from 18 to 75 years old;~* Established diagnosis of CHD;~* Previous (at least, within 1 month before inclusion in the present study) treatment with statin;~* Levels of plasma TC and LDL-C above the recommended target values~(TC\> 4.5 mmol\\L; LDL-C\> 2.5 mmol/L);~* The written informed consent signed prior to the start of participation in the study.~Exclusion Criteria:~* Contraindications for statin and ezetimibe (Ezetrol) administration in accordance with local Russian Federation medical instructions.~* Patients refused to participate in the study and/or did not sign informed consent form.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- New Statin (Type: None): Group 1 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) whose lipid-lowering therapy was modified by transition to a new statin treatment
- Statin Dose Titration (Type: None): Group 2 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) whose lipid-lowering therapy was modified by increasing the dose of ongoing statin treatment
- Ezetimibe added to existing statin (Type: None): Group 3 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) and whose lipid-lowering therapy was modified by the addition of ezetimibe to ongoing statin treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).